Opus Genetics Inc (IRD): Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Risks associated with rare pathologies and insurance complexities drive the historical trend of next year's EPS forecast, where 34.20 represents the current level of the metric. Opus Genetics Inc (IRD) aims for dominance in retinal treatment niches through genome correction. Meanwhile, GMP-certified laboratories ensure the production of pilot drug batches without equipment wear and tear.

IRD - Prakiraan wutah bathi kanggo taun ngarep Opus Bio ing rentang 25.10.2024 - 11.11.2026

Opus Genetics - rincian analitis lan metrik utama (IRD)

- rega lan prakiraan konsensus rega:

Bagan rega Opus Genetics, Inc.|IRD - Rata-rata rega prakiraan

- data kapitalisasi bursa:

Nilai pasar Opus Genetics|IRD - Nilai Wutuh Bisnis

- rincian nilai buku perusahaan:

Nilai Akuntansi saben Saham Opus Genetics|IRD - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku opusgtx.com|IRD - Gunggung Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Rasio Total Utang marang Ekuitas Opus Genetics Inc|IRD - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Opus Genetics, Inc.|IRD - Tanggungan utang total perusahaan|Utang-utang marang kapitalisasi buku Opus Genetics|IRD - Utang jangka dawa|Utang jangka cendhak perusahaan Opus Genetics|Rasio cepet opusgtx.com

- statistik bathi lan rasio pasar:

IRD - Penghasilan resik perusahaan|Bathi mangsa ngarep Opus Genetics Inc|IRD - Rasio rega pasar marang bathi resik|Pangali Forward P/E Opus Genetics, Inc.|IRD - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA Opus Genetics|IRD - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Opus Genetics|IRD - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan opusgtx.com|IRD - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Opus Genetics Inc

Analisis kabeh metrik perusahaan:Opus Genetics Inc, IRD

Opus Genetics Inc (IRD) is investing significant resources into gene therapy R&D, making its financial stability dependent on future drug registrations. The current value of 34.20 reflects the analysts' consensus forecast for next year's profit changes, quantifying market expectations regarding the company's transition to monetization. By analyzing shifts in analyst expectations for EPS growth in year n+1, an investor can identify an overvaluation of the asset in the event of overly optimistic forecasts.

Pesaing Opus Genetics Inc